Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYingying WuUnion HospitalZCZhipeng ChengUnion HospitalAZAo ZhangUnion Hospital

Discussion

Loading...

Member takes

Overview

Single-center analysis shows high complete response and safety in DLBCL patients treated with polatuzumab vedotin-based regimens.

Key Points

  • To assess the efficacy and safety of polatuzumab vedotin-based regimens in newly diagnosed diffuse large B-cell lymphoma patients.
  • Retrospective analysis of 42 newly diagnosed DLBCL patients treated with Pola-based regimens
  • Treatment regimens included Pola-R-CHP, Pola-miniCHP, Pola-ZR, among others
  • Clinical data collected included response rates, survival, and adverse events.
  • Overall response rate (ORR) for all Pola-based regimens was 90.5%
  • Complete response (CR) rate was 71.4%, with a progressive disease (PD) rate of 9.5%
  • Estimated 1-year overall survival (OS) was 92.9% and progression-free survival (PFS) was 88.1%.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e28fhttps://doi.org/10.1182/blood-2025-7207
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025
  2. 2Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  3. 3A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  4. 4Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China2025
  5. 5Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China2025